Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 760273102 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Blue Owl Capital Holdings LP 13G/A Amendment 2 | 0% |
5/14/2026
Event 3/31/2026
|
|
|
Biotechnology Value Fund L P
13D/A
Amendment 3
|
0% |
1/30/2026
Event 1/28/2026
|
|
| Biotechnology Value Fund L P | 0% | ||
| BVF I GP LLC | 0% | ||
| Biotechnology Value Fund II LP | 0% | ||
| BVF II GP LLC | 0% | ||
| Biotechnology Value Trading Fund OS LP | 0% | ||
| BVF Partners OS Ltd. | 0% | ||
| BVF GP Holdings LLC | 0% | ||
| BVF Partners L P/IL | 0% | ||
| BVF Inc/IL | 0% | ||
| Lampert Mark N | 0% | ||
|
Shay Capital LLC
13G
|
6.7% |
1/27/2026
Event 1/20/2026
|
|
| Shay Capital LLC | 6.7% | ||
| Shay Capital Holdings LLC | 6.7% | ||
|
Biotechnology Value Fund L P
13D/A
Amendment 2
|
24.0% |
11/24/2025
Event 11/20/2025
|
|
| Biotechnology Value Fund L P | 12.4% | ||
| BVF I GP LLC | 12.4% | ||
| Biotechnology Value Fund II LP | 10.0% | ||
| BVF II GP LLC | 10.0% | ||
| Biotechnology Value Trading Fund OS LP | 1.3% | ||
| BVF Partners OS Ltd. | 1.3% | ||
| BVF GP Holdings LLC | 22.4% | ||
| BVF Partners L P/IL | 24.0% | ||
| BVF Inc/IL | 24.0% | ||
| Lampert Mark N | 24.0% | ||
|
Versant Venture Capital V, L.P.
13D/A
Amendment 6
|
0.2% |
11/21/2025
Event 11/19/2025
|
|
| Versant Venture Capital V, L.P. | 0% | ||
| Versant Affiliates Fund V, L.P. | 0% | ||
| Versant Ophthalmic Affiliates I, L.P. | 0% | ||
| Versant Ventures V, LLC | 0% | ||
| Versant Venture Capital V (Canada) LP | 0% | ||
| Versant Ventures V (Canada), L.P. | 0% | ||
| Versant Ventures V GP-GP (Canada), Inc. | 0% | ||
| Versant Venture Capital VI, L.P. | 0% | ||
| Versant Ventures VI GP, L.P. | 0% | ||
| Versant Ventures VI GP-GP, LLC | 0% | ||
| Versant Vantage I, L.P. | 0.2% | ||
| Versant Vantage I GP, L.P. | 0.2% | ||
| Versant Vantage I GP-GP, LLC | 0.2% | ||
| ARK Investment Management LLC 13G/A Amendment 3 | 4.7% |
2/14/2025
Event 12/31/2024
|
|
|
MPM BioVentures 2014, L.P.
13D/A
Amendment 7
|
4.6% |
1/31/2025
Event 1/31/2025
|
|
| MPM BioVentures 2014, L.P. | 2.4% | ||
| MPM BioVentures 2014 (B), L.P. | 0.2% | ||
| MPM Asset Management Investors BV2014 LLC | 0.1% | ||
| UBS Oncology Impact Fund L.P. | 1.9% | ||
| MPM BioVentures 2014 GP LLC | 2.6% | ||
| MPM BioVentures 2014 LLC | 2.6% | ||
| Oncology Impact Fund (Cayman) Management L.P. | 1.9% | ||
| MPM BioImpact LLC | 1.9% | ||
| Ansbert Gadicke | 4.6% | ||
| Luke Evnin | 2.6% | ||
| Todd Foley | 2.6% | ||
|
MPM BioVentures 2014, L.P.
13D/A
Amendment 6
|
5.1% |
1/15/2025
Event 1/13/2025
|
|
| MPM BioVentures 2014, L.P. | 2.7% | ||
| MPM BioVentures 2014 (B), L.P. | 0.2% | ||
| MPM Asset Management Investors BV2014 LLC | 0.1% | ||
| UBS Oncology Impact Fund L.P. | 2.1% | ||
| MPM BioVentures 2014 GP LLC | 2.8% | ||
| MPM BioVentures 2014 LLC | 2.9% | ||
| Oncology Impact Fund (Cayman) Management L.P. | 2.1% | ||
| MPM BioImpact LLC | 2.1% | ||
| Ansbert Gadicke | 5.1% | ||
| Luke Evnin | 2.9% | ||
| Todd Foley | 2.9% | ||
|
MPM BioVentures 2014, L.P.
13D/A
Amendment 5
|
6.3% |
1/6/2025
Event 1/2/2025
|
|
| MPM BioVentures 2014, L.P. | 3.3% | ||
| MPM BioVentures 2014 (B), L.P. | 0.2% | ||
| MPM Asset Management Investors BV2014 LLC | 0.1% | ||
| UBS Oncology Impact Fund L.P. | 2.6% | ||
| MPM BioVentures 2014 GP LLC | 3.5% | ||
| MPM BioVentures 2014 LLC | 3.6% | ||
| Oncology Impact Fund (Cayman) Management L.P. | 2.6% | ||
| MPM BioImpact LLC | 2.6% | ||
| Ansbert Gadicke | 6.3% | ||
| Luke Evnin | 3.6% | ||
| Todd Foley | 3.6% | ||
|
MPM BioVentures 2014, L.P.
13D/A
Amendment 4
|
7.8% |
12/26/2024
Event 12/20/2024
|
|
| MPM BioVentures 2014, L.P. | 4.1% | ||
| MPM BioVentures 2014 (B), L.P. | 0.3% | ||
| MPM Asset Management Investors BV2014 LLC | 0.1% | ||
| UBS Oncology Impact Fund L.P. | 3.3% | ||
| MPM BioVentures 2014 GP LLC | 4.3% | ||
| MPM BioVentures 2014 LLC | 4.5% | ||
| Oncology Impact Fund (Cayman) Management L.P. | 3.3% | ||
| MPM BioImpact LLC | 3.3% | ||
| Ansbert Gadicke | 7.8% | ||
| Luke Evnin | 4.5% | ||
| Todd Foley | 4.5% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q4 | 54 | 25.4 M | $66.0 M |
| 2025 Q3 | 49 | 27.5 M | $48.4 M |
| 2025 Q2 | 55 | 27.9 M | $38.7 M |
| 2025 Q1 | 52 | 29.5 M | $29.1 M |
| 2024 Q4 | 56 | 30.6 M | $40.1 M |
| 2024 Q3 | 59 | 32.4 M | $111 M |
| 2024 Q2 | 67 | 34.1 M | $113 M |
| 2024 Q1 | 78 | 36.1 M | $170 M |
| 2023 Q4 | 76 | 36.9 M | $269 M |
| 2023 Q3 | 87 | 36.3 M | $438 M |
| 2023 Q2 | 81 | 35.8 M | $379 M |
| 2023 Q1 | 81 | 33.2 M | $327 M |
| 2022 Q4 | 87 | 33.5 M | $493 M |
| 2022 Q3 | 75 | 32.8 M | $398 M |
| 2022 Q2 | 77 | 33.2 M | $452 M |
| 2022 Q1 | 66 | 32.6 M | $465 M |
| 2021 Q4 | 72 | 32.7 M | $690 M |
| 2021 Q3 | 72 | 27.0 M | $708 M |
| 2021 Q2 | 66 | 26.5 M | $828 M |
| 2021 Q1 | 66 | 26.0 M | $798 M |
| 2020 Q4 | 66 | 27.4 M | $941 M |
| 2020 Q3 | 40 | 23.9 M | $735 M |
| 2020 Q2 | 49 | 23.0 M | $709 M |
| 2020 Q1 | 1 | 100 | $3.00 k |
| 2019 Q4 | 1 | 100 | $3.00 k |
| 2019 Q3 | 1 | 100 | $3.00 k |
| 2019 Q2 | 1 | 100 | $3.00 k |
| 2019 Q1 | 1 | 100 | $3.00 k |